A dramatic rise in viruses — from measles to RSV — underscores a growing health crisis.
As vaccines falter and cases rise, the need for a new approach to treatment is greater than ever.

Some companies pursue vaccines — this small innovator is developing a direct-acting, broad-spectrum drug designed to attack viruses directly, regardless of mutations.

Here’s what makes it different:

➥ It has demonstrated the ability to clear viruses completely in preclinical models.
➥ It’s currently progressing toward human trials against measles — a disease for which there is no approved treatment.
➥ The drug’s unique mechanisms allow it to be broadly applicable against numerous viruses — from flu and COVID variants to the resurgent measles — with 90–95% coverage of human viruses.

This tiny biotech — with a small float and a market cap under $30M — may be poised to become a key player in the future of antivirals.

With the global biotech market expected to nearly triple by 2030, companies developing powerful, versatile treatments could find themselves well positioned for growth — and for delivering significant gains to forward-thinking investors.

Don’t miss this opportunity to learn more.

This message is a PAID ADVERTISEMENT for NanoViricides, Inc (NYSE: NNVC) from Interactive Offers. StockEarnings, Inc. has received a fixed fee of $7000 from Interactive Offers for multiple Dedicated Email Sends, Newsletter Sponsorships and SMS Sends between June 26, 2025 and July 2, 2025. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either NanoViricides, Inc (NYSE: NNVC) or Interactive Offers. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding NanoViricides, Inc (NYSE: NNVC) on Smallcaps Daily website for additional information about the relationship between Interactive Offers and NanoViricides, Inc (NYSE: NNVC).

Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe.

StockEarnings, Inc
33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA
W: 877.6.STOCKS
StockEarnings.com